Patent Information:
For Information, Contact:
Rachel Hemsley
Senior Business Manager
UCL Business PLC
020 7679 9000
r.hemsley@uclb.com
Keywords:
Central Nervous System (CNS)
Ophthalmology & Optometry

Early Diagnosis of Alzheimer's Disease

Case ID:
88-086
Web Published:
25/03/2015
Description:

Available for: Exclusive Licensing/Non-exclusive Licensing

<h2>Summary</h2>

{{start}} Alzheimer Disease (AD) is the most common neurodegenerative disorder affecting half of all the people above 80 years of age. The available diagnostic methods are expensive and are not available to all patients. An easily detectable biomarker that could be used for diagnosis and monitoring of AD is needed. Researchers at UCL Institute of Ophthalmology demonstrated that measuring drusen deposits in the periphery of the eye can be used as diagnostic method for AD. {{end}}

<h2>The Technology and its Advantages</h2>

Several markers for early detection of AD exist with PET studies of amyloid deposition and brain metabolism, MR imaging of celebrar athropy and CSF tau sampling being the gold standard. These, however, are expensive and require significant patient compliance. The MRI scans are also often not available for elderly patients due to their contradictions. Researchers at UCL Institute of Ophthalmology identified that retinal drusen, an amyloid plaque-like depositing at the macular periphery can provide indirect measure of amyloid beta deposition in the brain. Drusen imaging is fast, requires little compliance from the patient, can be sampled serially and is cheaper as compared to the methods used for diagnosing AD currently.

<h2>Market Opportunity</h2>

The global market size for Alzheimer's Disease therapeutics was estimated at $3.6billion in 2014 and expected to grow to $6.5billion in 2022. AD is a challenge to care givers, families and health care systems all over the world. The prevalence of Alzheimer's Disease rises steeply with age and as current projections estimate that the number of elderly people will double in the next generation, so will the prevalence of AD. The current understanding of the disease is that the greatest therapeutic effects can be achieved if the AD could be diagnosed early. The early symptoms of AD, however, are associated with normal aging and as the current diagnostic methods are complicated and costly, many patients do not become diagnosed until the disease is developed. Therefore lowering the cost and simplification of diagnosis and monitoring of AD are the greatest unmet medical needs in the context of a growing elderly population.

<h2>Intellectual Property Status</h2>

Patent Pending (US13/772600)

<h2>Further Information</h2>

Please contact Dr Rachel Hemsley, Senior Business Manager |T: +44 (0)20 7679 9000 | E: r.hemsley@uclb.com  

© 2017. All Rights Reserved. Powered by Inteum